Amsterdam institute for Immunology and Infectious diseases
AI&I news
From D25 to Nirsevimab: A Dutch Discovery that Changed Infant Health WorldwideIn 2007, a breakthrough in respiratory medicine was made in Amsterdam. Prof. Hergen Spits and his team, isolated a potent antibody, D25, from a single immune cell of a Dutch blood donor. This antibody targeted the respiratory syncytial virus (RSV), a common cold virus that poses a serious threat to infants. Today, its optimized successor, nirsevimab, is part of the national immunization program, preventing thousands of hospitalizations each year in the Netherlands and beyond.
Decline in Annual Number of New HIV Diagnoses in the Netherlands Has StoppedThis is the main finding from the 2025 HIV Monitoring Report for the Netherlands published by Stichting hiv monitoring (SHM) on 20 November 2025. Since 2010, the number of HIV diagnoses in the Netherlands was decreasing steadily, but the decline has stalled in recent years. In 2024, 444 new HIV diagnoses were registered.
Run for Their Lives: Meet the AI&I Runners – Joppe HoviusOn March 15, AI&I researchers will lace up their running shoes for the Amstelveen Spring Marathon, raising funds for research into Post-Acute Infection Syndromes (PAIS). Every donation supports innovative projects to improve diagnosis, treatment, and quality of life for PAIS patients.
